Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00026312 · ClinicalTrials.gov registry record · Phase 3
Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma
A Phase 3 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 3
- Development phase
- 1,449
- Enrollment target
NCT00026312: Completed Phase 3 study, sponsored by National Cancer Institute (NCI).
NCT00026312 is a Phase 3 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 1,449 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00026312, a Phase 3 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,449 participants
- Enrollment target
Study Summary
This partially randomized phase III trial studies isotretinoin with dinutuximab, aldesleukin, and sargramostim to see how well it works compared to isotretinoin alone following stem cell transplant in treating patients with neuroblastoma. Drugs used in chemotherapy, such as isotretinoin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as dinutuximab, may block tumor growth in different ways by targeting certain cells. Aldesleukin and sargramostim may stimulate a person's white blood cells to kill cancer cells. It is not yet known if chemotherapy is more effective with or without dinutuximab, aldesleukin, and sargramostim following stem cell transplant in treating neuroblastoma.
Interventions
- OTHER Laboratory Biomarker Analysis
- BIOLOGICAL Aldesleukin
- DRUG Isotretinoin
- OTHER Pharmacological Study
- BIOLOGICAL Dinutuximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,449 participants |
| Start Date | 2001-10-26 |
| Est. Completion | 2025-12-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00026312
The ClinicalTrials.gov registry entry for NCT00026312 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,449 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT00026312 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00026312 about?
NCT00026312 is a clinical study titled "Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma". This partially randomized phase III trial studies isotretinoin with dinutuximab, aldesleukin, and sargramostim to see how well it works compared to isotretinoin alone following stem cell transplant in treating patients with neuroblastoma. Drugs used in chemotherapy, such as isotretinoin, work in dif...
What is the current status of trial NCT00026312?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,449 participants. The study started on 2001-10-26. Estimated completion is 2025-12-31.
What interventions are being tested in trial NCT00026312?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Aldesleukin (BIOLOGICAL), Isotretinoin (DRUG), Pharmacological Study (OTHER), Dinutuximab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00026312?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.